Pulmonx (LUNG) Capital Expenditures Growth (1y) (2020 - 2025)
Pulmonx (LUNG) Capital Expenditures Growth (1y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.14 Bn | 173.84 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 128.35 Bn | 125.47 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 107.95 Bn | 98.73 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 68.16 Bn | 66.71 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 47.67 Bn | 44.00 Bn | 1.29 Bn | 15.89% |
| 6 | GE HealthCare Technologies | 28.45 Bn | 26.17 Bn | 1.98 Bn | 106.98% |
| 7 | Dexcom | 28.45 Bn | 27.33 Bn | 750.30 Mn | -11.95% |
| 8 | Smith & Nephew | 26.83 Bn | 26.25 Bn | - | - |
| 9 | Koninklijke Philips | 25.36 Bn | 22.23 Bn | 2.07 Bn | -47.73% |
| 10 | Pulmonx | 50.56 Mn | -19.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 60.16% |
| Jun 30, 2025 | -92.93% |
| Mar 31, 2025 | 201.00% |
| Dec 31, 2024 | 225.00% |
| Sep 30, 2024 | -1,277.03% |
| Jun 30, 2024 | 268.72% |
| Mar 31, 2024 | -78.68% |
| Dec 31, 2023 | 107.25% |
| Sep 30, 2023 | -73.48% |
| Jun 30, 2023 | -262.54% |
| Mar 31, 2023 | -16.84% |
| Dec 31, 2022 | -119.70% |
| Sep 30, 2022 | 132.03% |
| Jun 30, 2022 | -60.61% |
| Mar 31, 2022 | 291.67% |
| Dec 31, 2021 | 425.11% |
| Sep 30, 2021 | -548.97% |
| Jun 30, 2021 | 200.00% |
| Mar 31, 2021 | 162.88% |
| Dec 31, 2020 | 238.05% |